NVXCoV 2373
Alternative Names: Coronavirus vaccine - Novavax; COVID-19 vaccine - Novavax; COVOVAX; Covovax; Nuvaxovid; NVX-CoV-2373; NVX-CoV2601; NVX-CoV2705; NVX‑CoV2373 vaccine; Recombinant spike protein of SARS-CoV-2 virus vaccine; SARS-CoV-2 recombinant spike protein nanoparticle vaccine; SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine - Novavax; SARS-CoV-2 rS nanoparticle vaccine; TAK-019Latest Information Update: 09 Jul 2024
At a glance
- Originator Novavax
- Developer Novavax; Serum Institute of India; Takeda
- Class Adjuvants; COVID-19 vaccines; Protein vaccines; Synthetic vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed COVID 2019 infections
Most Recent Events
- 02 Jul 2024 Novavax files for authorization of NVX-CoV2705 for the treatment of patients with COVID-2019 infection (Prevention, 12 years and older) in Canada (IM, injection)
- 02 Jul 2024 Novavax files for authorization of NVX-CoV2705 for the treatment of patients with COVID-2019 infection (Prevention, 12 years and older) in USA (IM, injection) before July 2024
- 02 Jul 2024 Novavax intend to launch NVX-CoV2705 for the treatment of patients with COVID-2019 infection (Prevention, 12 years and older) in Canada